Professor Josef Vormoor

Finding new targets for leukaemia drugs

Based at Newcastle University, Professor Josef Vormoor and his team are looking into the biology of leukaemia, a cancer of the blood. More specifically, they’re focusing their interests on a type called acute lymphoblastic leukaemia (ALL), which most commonly affects children and young people.

Although there are effective treatments for ALL, people still die from this disease and sometimes the cancer can return after treatment is stopped. Importantly, current treatments for ALL can harm healthy cells and sometimes lead to serious side effects and long-term health problems.

Professor Vormoor and his team are looking to develop new combination therapies by targeting cellular pathways that the leukaemia cells depend on. Using modern molecular techniques, including gene editing, he is exploring new vulnerabilities in the cancer cells that could lead to new treatment avenues.

This research could help scientists and clinicians discover and develop new, more precise therapies that are kinder for patients, helping more people survive the disease.


Blood cancers
Cancer biology
Drug development

Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne